Elanco raises FY25 adjusted EPS view to 91c-94c, consensus 91c

Raises FY25 revenue view to $4.65B-$4.67B from $4.57B-$4.62B, consensus $4.6B. Raises FY25 adjusted EBITDA view to $880M-$900M from $850M-$890M. “I am pleased to have joined Elanco (ELAN) during this period of strong momentum,” said Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health. “Through consistent execution, we are again raising our 2025 full-year guidance, while also making incremental data-driven investments to power our innovation launches in this new era of growth. Additionally, we refinanced our $2.1 billion Term Loan B facility, extending the maturities through 2032. We expect our balance sheet to be in a strong position as we exit 2025, and we are excited to share more details at our December Investor Day on how Elanco is driving value creation through Elanco Ascend, our company-wide productivity initiative, as well as cash generation.”